ANI Pharmaceuticals' Eye-Care Franchise Faces New Competition, Oppenheimer Says

12:15 PM EDT, 10/22/2026 (MT Newswires) -- ANI Pharmaceuticals' (ANIP) ophthalmology franchise faces a potential new competitor after positive late-stage trial results for Roivant Sciences' (ROIV) Brepocitinib in non-infectious uveitis, posing a long-term risk to Iluvien and possibly affecting Cortrophin's eye-care opportunity, Oppenheimer said Wednesday in a report. Roivant's two phase 3 studies demonstrated that 62% of patients taking Brepocitinib had their eye inflammation controlled without steroids at week 48, compared with 20% on placebo, Oppenheimer said. Brepocitinib could potentially place about half of Iluvien sales at risk, Oppenheimer said. Iluvien is expected to generate about $80 million in 2026 sales and account for about 7% of ANI's revenue, the report said. Cortrophin could also face risks from Brepocitinib's emergence, though Oppenheimer said it sees no direct competitive implications for Cortrophin's other specialties, including a potential expansion into gout. Oppenheimer maintained its perform rating on ANI stock. ANI shares rose 1.4% in Thursday trading, and Roivant gained 2.8%. Price: 73.23, Change: +0.99, Percent Change: +1.37